Abingworth Announces Strategic Leadership Transition and Senior Appointments

On January 5, 2026, Abingworth — the transatlantic life sciences investment firm that is part of global investment firm Carlyle (NASDAQ: CG) — unveiled a significant leadership transition and new appointments as part of its ongoing strategy for growth and expanded investment impact. Kurt von Emster, who has served as Managing Partner and Head of Abingworth Life Sciences, will transition into the role of Managing Partner of Abingworth. In his new capacity, Kurt will continue to drive clinical co‑development investments, support venture investments, and advance the firm’s broader strategic vision. Dr. Bali Muralidhar, currently Managing Partner, Chief Investment Officer (CIO), and Chief Operating Officer (COO), has been appointed as the new Head of Abingworth Life Sciences and will also retain his role as CIO. His appointment reflects confidence in his leadership to guide Abingworth’s life sciences investment platform into the future. In addition, Travis Wilson has joined Abingworth and Carlyle as Managing Director. With over 20 years of experience in life sciences investing and executive roles, Wilson will focus on clinical co‑development and biotech and pharmaceutical buyout opportunities, strengthening Carlyle’s life sciences franchise. The new leadership changes are expected to bolster Abingworth’s position in advancing cutting‑edge science into novel medicines and enhancing long‑term value for investors and portfolio companies. #Abingworth #LeadershipTransition #LifeSciences #Carlyle #SlimScan #GrowthStocks #CANSLIM